Cargando…

HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems

Background: Highly active antiretroviral therapy (HAART) is complex and many factors contribute to a patient’s response to initial therapy including adherence, drug effectiveness, and tolerance. Close HAART follow-up is needed, particularly when there are concurrent therapies such as prophylactic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Molino, C.G.R.C., Carnevale, Renata Cavalcanti, Rodrigues, Aline Teotonio, Moriel, Patricia, Mazzola, Priscila Gava
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506733/
https://www.ncbi.nlm.nih.gov/pubmed/28725145
http://dx.doi.org/10.1016/j.jsps.2016.11.004
_version_ 1783249619797409792
author Molino, C.G.R.C.
Carnevale, Renata Cavalcanti
Rodrigues, Aline Teotonio
Moriel, Patricia
Mazzola, Priscila Gava
author_facet Molino, C.G.R.C.
Carnevale, Renata Cavalcanti
Rodrigues, Aline Teotonio
Moriel, Patricia
Mazzola, Priscila Gava
author_sort Molino, C.G.R.C.
collection PubMed
description Background: Highly active antiretroviral therapy (HAART) is complex and many factors contribute to a patient’s response to initial therapy including adherence, drug effectiveness, and tolerance. Close HAART follow-up is needed, particularly when there are concurrent therapies such as prophylactic antibiotics and medications for the treatment of comorbidities. Objective: To assess the effectiveness of pharmacist intervention in reducing drug related problems in HIV/AIDS outpatients (intervention group) and in improving clinical parameters in the intervention group compared to the control group. Methods: We conducted a prospective controlled intervention study with patients paired by gender and initial T CD4+ lymphocyte (CD4) count. HIV-infected patients of a public outpatient service were enrolled for the study by consecutive and convenience sampling. Patients selected for the study were divided into a control group and an intervention group. Both groups were followed for one year; however, only the intervention group received pharmaceutical care. The primary outcome was the drug related problem (DRP) analysis for the intervention group. Secondary outcomes were CD4 count and viral load evaluation for both groups. Results: There was a total of 143 patients enrolled in this study, with 53 (37.06%) patients in the control group and 90 (62.94%) patients in the intervention group. A total of 202 pharmacist interventions with 193 pharmacist-patient and 9 pharmacist-physician interventions were proposed. After one year of pharmaceutical care, a reduction of 38.43% between the initial and final DRP was found (p = 0.0001). The most common DRPs found were related to medication safety. The intervention group showed a mean increase of 84% for the CD4 count in comparison with that observed in the control group. The viral load was not significantly different between the final and initial mean values for both groups. Conclusion: Pharmacist appointments enabled identification, prevention, and solving of drug related problems, especially those related to drug safety. Also, pharmacist interventions improved adherence and increased HAART effectiveness as suggested by the higher elevation in the CD4 count seen in the intervention group in comparison with the control group.
format Online
Article
Text
id pubmed-5506733
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-55067332017-07-19 HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems Molino, C.G.R.C. Carnevale, Renata Cavalcanti Rodrigues, Aline Teotonio Moriel, Patricia Mazzola, Priscila Gava Saudi Pharm J Original Article Background: Highly active antiretroviral therapy (HAART) is complex and many factors contribute to a patient’s response to initial therapy including adherence, drug effectiveness, and tolerance. Close HAART follow-up is needed, particularly when there are concurrent therapies such as prophylactic antibiotics and medications for the treatment of comorbidities. Objective: To assess the effectiveness of pharmacist intervention in reducing drug related problems in HIV/AIDS outpatients (intervention group) and in improving clinical parameters in the intervention group compared to the control group. Methods: We conducted a prospective controlled intervention study with patients paired by gender and initial T CD4+ lymphocyte (CD4) count. HIV-infected patients of a public outpatient service were enrolled for the study by consecutive and convenience sampling. Patients selected for the study were divided into a control group and an intervention group. Both groups were followed for one year; however, only the intervention group received pharmaceutical care. The primary outcome was the drug related problem (DRP) analysis for the intervention group. Secondary outcomes were CD4 count and viral load evaluation for both groups. Results: There was a total of 143 patients enrolled in this study, with 53 (37.06%) patients in the control group and 90 (62.94%) patients in the intervention group. A total of 202 pharmacist interventions with 193 pharmacist-patient and 9 pharmacist-physician interventions were proposed. After one year of pharmaceutical care, a reduction of 38.43% between the initial and final DRP was found (p = 0.0001). The most common DRPs found were related to medication safety. The intervention group showed a mean increase of 84% for the CD4 count in comparison with that observed in the control group. The viral load was not significantly different between the final and initial mean values for both groups. Conclusion: Pharmacist appointments enabled identification, prevention, and solving of drug related problems, especially those related to drug safety. Also, pharmacist interventions improved adherence and increased HAART effectiveness as suggested by the higher elevation in the CD4 count seen in the intervention group in comparison with the control group. Elsevier 2017-07 2016-11-15 /pmc/articles/PMC5506733/ /pubmed/28725145 http://dx.doi.org/10.1016/j.jsps.2016.11.004 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Molino, C.G.R.C.
Carnevale, Renata Cavalcanti
Rodrigues, Aline Teotonio
Moriel, Patricia
Mazzola, Priscila Gava
HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems
title HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems
title_full HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems
title_fullStr HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems
title_full_unstemmed HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems
title_short HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems
title_sort hiv pharmaceutical care in primary healthcare: improvement in cd4 count and reduction in drug-related problems
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506733/
https://www.ncbi.nlm.nih.gov/pubmed/28725145
http://dx.doi.org/10.1016/j.jsps.2016.11.004
work_keys_str_mv AT molinocgrc hivpharmaceuticalcareinprimaryhealthcareimprovementincd4countandreductionindrugrelatedproblems
AT carnevalerenatacavalcanti hivpharmaceuticalcareinprimaryhealthcareimprovementincd4countandreductionindrugrelatedproblems
AT rodriguesalineteotonio hivpharmaceuticalcareinprimaryhealthcareimprovementincd4countandreductionindrugrelatedproblems
AT morielpatricia hivpharmaceuticalcareinprimaryhealthcareimprovementincd4countandreductionindrugrelatedproblems
AT mazzolapriscilagava hivpharmaceuticalcareinprimaryhealthcareimprovementincd4countandreductionindrugrelatedproblems